Effect of intravitreal bevacizumab in diabetic macular edema

Abstract

Objective: To report the effect of intravitreal bevacizumab (Avastin) on visual acuity and central macular thickness in patients with diabetic macular edema (DME), who have already received macular laser photocoagulation.
Methodology: This Prospective, interventional case series study was conducted at the Department of Ophthalmology, Isra University and Hospital, Hyderabad, and Al-Ibrahim Eye Hospital, Karachi, from July 2009 to March 2010. Twenty four eyes with diffuse DME were treated with intravitreal injection of bevacizumab 1.25mg in 0.05ml. Evaluation at baseline and follow-up visits included visual acuity by ETDRS chart, slit lamp examination, applanation tonometry, fundus fluorescein angiography, and macular thickness measurement by optical coherence tomography. Central macular thickness on optical coherence tomography (OCT) and best corrected visual acuity were measured at baseline and at one month and three months after the intravitreal injection.
Results: At baseline, the mean BCVA was 1.033